Floatz logo

Fluzone

MELAS Syndrome

Stanford UniversityUNKNOWNPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the MELAS Syndrome cohort.

Asset / SponsorPhaseRating
Sonlicromanol
Khondrion BV
Phase 3BB
Idebenone
Michio Hirano
Phase 2B
ARG
The Hospital for Sick Children
Phase 2B
Zagociguat
Tisento Therapeutics
Phase 2CCC
Tti-0102
Thiogenesis Therapeutics, Inc.
Phase 2CCC

View all 10 →

Same molecule, other indications

Fluzone is also rated in:

influenzaDormant
B
Indicative · Phase 2
57 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
B
Indicative · Phase 2
57 / 100
View asset →
lymphomaActive
B
Indicative · Phase 4
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →